(and so calculation of CPP), although their value has not been tested in a clinical trial. However, accumulating data from clinical studies that use other intracranial monitors such as microdialysis, PET, or MR imaging show that secondary brain injury is not always associated with pathological changes in ICP or CPP and that mechanisms other than simple perfusionlimited abnormalities may be responsible for cellular injury after TBI. 5, 24, 27, 33, 49, 59 These data suggest that newer monitors (for example, microdi alysis or direct brain oxygen [PbtO 2 ] monitors) may have a role in the care of patients with TBI. The brain is highly dependent on a continuous sup ply of oxygen and glucose (aerobic metabolism) to main tain cellular integrity. 3, 45 This metabolism is altered af ter severe TBI and brain hypoxia is common in patients with this condition. 16, 19, 51 Observational clinical studies demonstrate a significant association between poor pa tient outcome and the number, duration, and intensity of brain hypoxic episodes (PbtO 2 < 15 mm Hg) after severe TBI. 4, 13, 23, [55] [56] [57] [58] In addition, converging experimental and clinical evidence suggest that therapy to augment or cor rect PbtO 2 may improve TBI outcome. 17, 40, 46, 47, 53 In a small preliminary clinical study that included 53 patients we observed that PbtO 2 directed therapy was associated with a lower mortality rate than was seen in patients identified from a historical cohort who received only ICP and CPPdirected treatment. 50 In the current study we examined how PbtO 2 -directed therapy influenced patient outcome in a larger cohort (123 patients) that included new patients not examined in our original study. We hypothesized the following: 1) PbtO 2 directed therapy combined with ICP/ CPP-based therapy was associated with a reduced mor tality rate and better shortterm outcome than ICP/CPPbased therapy alone; and 2) successful treatment of com promised PbtO 2 would improve outcome.
Methods

Patient Population
Patients with severe TBI admitted to the Hospital of the University of Pennsylvania (HUP), a Level I trauma center, within 8 hours of TBI were eligible for this study. Patients were identified retrospectively from a prospec tive observational database with institutional review board approval. Study inclusion criteria were patient age ≥ 16 years, a postresuscitation admission GCS score ≤ 8, an ISS ≥ 16, and a head CT scan to exclude other causes for their condition. Patients who at admission were 1) brain dead, 2) had bilateral fixed and dilated pupils, 3) had a penetrating TBI, or 4) had a previous CNS disease or TBI were excluded from analysis. In addition, patients whose postresuscitation systolic blood pressure was < 90 mm Hg or SaO 2 < 90% were not included in this study. Two groups of patients, each from a defined time period before or after we introduced formal PbtO 2 monitoring and management protocols to our institution (October 2001) and between January 2000 and September 2004, were identified. Patients treated in the 3 months before or after the introduction of PbtO 2 monitoring at our institu tion were not considered for analysis. The control group (Group I), a historical cohort population who received only an ICP monitor for ICP/CPP-directed therapy was identified retrospectively from the HUP Prospective TBI database. The study population (Group II) consisted of patients who received an ICP and PbtO 2 monitor and PbtO 2 directed care and are included in our Brain Oxy gen Monitoring Outcome database.
Monitoring
Patients were cared for in the Neurosurgical and Trauma Intensive Care Unit. Heart rate, blood pressure as measured via an arterial catheter, and SaO 2 were record ed in all patients. Each Group I patient was monitored using a Camino ICP monitor (Integra NeuroSciences), whereas Group II patients received ICP, PbtO 2 , and brain tissue temperature monitors (LICOX, Integra NeuroSci ences). Intracranial monitors were inserted at the bedside through a bur hole into the frontal lobe and secured with a triplelumen bolt. The monitors were placed into white matter that appeared normal on admission head CT and on the side of maximum pathology. When there was no asymmetry in pathology on head CT, the monitors were placed in the right frontal region. If the patient had un dergone a craniotomy, the probes were placed on the same side as the injury if the craniotomy flap permitted. Followup noncontrast head CT scans were performed in all patients within 24 hours of admission to confirm correct placement of the various monitors (for example, not in a contusion or infarct). Probe function and stability were confirmed by an appropriate PbtO 2 increase follow ing an O 2 challenge (FiO 2 1.0 for 5 minutes). Each patient was monitored for at least 72 hours unless care was with drawn or the patient died during that period. Intracranial monitors were removed only when ICP was normal (< 20 mm Hg) for 24 hours without treatment except seda tion for ventilation. All physiological variables were con tinuously recorded using a bedside critical care monitor system (Component Monitoring System M1046-9090C, Hewlett Packard).
Management
Each patient was resuscitated and managed accord ing to a standard policy adapted to local practice from published recommendations for severe TBI and ICU care. 2, 7, 8, 42 This included the following: 1) early identifica tion and evacuation of traumatic hematomas; 2) intubation and ventilation with FiO 2 and minute ventilation adjusted to maintain SaO 2 > 93% and to avoid PaO 2 < 60 mm Hg; 3) PaCO 2 was set at approximately 35-45 mm Hg unless ICP was elevated when PaCO 2 was maintained between 30 and 40 mm Hg; 4) sedation using propofol during the first 24 hours, followed by sedation and analgesia using lorazepam, morphine, or fentanyl; 4) bed rest with head elevation of 15-30° and knee elevation; 5) normothermia (~ 35-37°C); 6) euvolemia using a baseline crystalloid infusion (0.9% normal saline, 20 mEq/L KCl; 80-100 ml/hour); and 7) anticonvulsant therapy (phenytoin) for 1 week or longer if seizures occurred.
The treatment goal for Group I patients (those treated with conventional ICP/CPP-guided therapy) was to keep ICP < 20 mm Hg and CPP > 60 mm Hg. A standard stairstep approach was used to treat intracranial hyper tension (ICP > 20 mm Hg for more than 2 minutes). Ini tial management consisted of elevation of the head of the bed, sedation (lorazepam), analgesia (fentanyl), intermit tent CSF drainage using an external ventricular drain if inserted, and moderate hyperventilation. If ICP remained > 20 mm Hg for > 10 minutes despite the initial manage ment, osmotherapy using mannitol boluses (0.5-1 g/kg) was started, provided that serum osmolality was < 320 mOsm/L and serum Na + < 155 mmol/L. Phenylephrine (10-100 mcg/minute) was administered when CPP was ≤ 60 mm Hg for > 15 minutes and after adequate fluid re suscitation. If the patient's ICP remained elevated despite mannitol, a ventriculostomy (if one had not been placed at admission) was inserted to drain CSF. Thereafter, opti mized hyperventilation (PaCO 2 ~ 30 mm Hg), additional propofol, or a decompressive hemicraniectomy were used as secondtier therapies if ICP and CPP remained com promised. Pentobarbitalinduced burst suppression was used if decompressive craniectomy failed to control ICP. Induced hypothermia for ICP control and hypertonic sa line were not used in either treatment group since they were formally introduced into our treatment protocols in October 2006 and May 2006, respectively.
Group II patients (the PbtO 2 guided therapy group) received the same ICP and CPP treatment as Group I patients. In addition, Group II patients, received "cause directed" therapy to maintain PbtO 2 ≥ 20 mm Hg. 39, 60 In our previous study we used a PbtO 2 threshold of 25 mm Hg. 50 Initial intervention included an O 2 challenge (100% FiO 2 ) or increased CPP to improve PbtO 2 . Pulmonaryas sociated or ventilationassociated PbtO 2 reductions were assessed for and corrected. Then ICP, metabolic delivery (for example, volume status or mean arterial blood pres sure) or demand (for example, pain, fever, seizures) abnor malities were corrected. If these measures failed, a blood transfusion was administered to achieve a hemoglobin ≥ 10 mg/dl. 48 A decompressive craniectomy was performed when there was a progressive PbtO 2 decline, or when the PbtO 2 was < 20 mm Hg for > 15 minutes despite maximal medical management for elevated ICP.
Data Collection
For each patient, the number of days and hours moni tored, daily maximum ICP, daily mean ICP, number and duration of episodes of increased ICP (≥ 20 mm Hg), daily minimum CPP, daily mean CPP, and number and duration of episodes of CPP < 60 mm Hg during the en tire monitoring period were recorded. For each Group II patient, the daily minimum and maximum PbtO 2 , daily mean PbtO 2 , number and duration of episodes of compro mised PbtO 2 (< 20 mm Hg), and number and duration of episodes of cerebral hypoxia (PbtO 2 < 15 mm Hg) were also recorded. The relevant variables and patient charac teristics were then compared between the groups to deter mine if there were any significant differences.
Outcome
Patient mortality rates were calculated on the basis of deaths during the first 3 months following TBI. Patient disposition was recorded and divided into 2 groups: 1) discharged home or to rehabilitation; or 2) patient died or was discharged to a nursing home or required ongo ing hospital care for their head injury. Shortterm patient outcome at 3 months (± 2 weeks) postTBI was assessed using the GOS by telephone followup or medical record review. Outcome was recorded as favorable if the patient had a good outcome or only moderate disability and un favorable if the patient died, was in a vegetative state, or had severe disability.
Statistical Analysis
Statistical analyses were performed using commer cially available software, SAS version 9.0 (SAS Institute, Inc.) and Instat Version 2.03 (GraphPad Software). Data are expressed as the mean ± SD or as the median where the data are not normally distributed. Patient and physi ological variables and outcome were compared using the KruskalWallis nonparametric ANOVA test, Student t test, chisquare approximate test, or the MannWhitney Fisher exact test, selected for their appropriateness to the measurement level and distributional properties of the data. Random effects models were used to adjust for clustering of repeated daily measurements in patients re ceiving PbtO 2 guided management when comparing the 2 groups. Statistical significance was defined as a 2-sided p < 0.05.
Results
Patient Characteristics
Fiftythree patients, 42 male and 11 female (mean age 43 ± 18 years), who received ICP/CPP-directed TBI care formed the historical control group, Group I. Group II (patients receiving PbtO 2 directed care) consisted of 70 patients, 57 male and 13 female (mean age 40.1 ± 19 years). Age, sex, admission GCS and ISS, and the pathol ogy observed on initial head CT were similar in the 2 groups (Table 1) . Apart from a slightly higher incidence of assault among Group II patients (11 vs 2%, p = 0.04), the mechanisms of injury were similar in both groups. A similar number of patients underwent craniotomy for a mass lesion at admission (10 in Group I and 18 in Group II, p = 0.5). Variables such as temperature, hematocrit, pulmonary function, and serum glucose level that may influence PbtO 2 or outcome are listed in Table 2 . The mean PaO 2 /FiO 2 ratio was greater in Group II patients, since transient hyperoxia (FiO 2 1.0) or an increase in FiO 2 (for example, from 50 to 60%) was used to treat compro mised PbtO 2 . Device malfunction, drift, or complications were rare (< 1%) in both treatment groups. Secondtier therapies such as barbiturates were used infrequently (1 case in each group). However decompressive craniectomy was more frequently performed in patients who received PbtO 2 guided management (performed in 9 cases) than in those who received ICP/CPP-guided therapy (performed in 1 case, p = 0.04).
Intracranial and Cerebral Perfusion Pressure
Data were obtained from a total of 12,148.8 hours of continuous ICP monitoring in the ICU from the 123 patients included in this study. There was a trend toward a longer period of monitoring among Group II patients (mean 4.7 ± 3.8 days in Group II vs 3.5 ± 2.9 days in Group I, p = 0.056). The mean values for daily mean ICP and daily mean calculated CPP, mean number of daily episodes of elevated ICP (ICP > 20 mm Hg), or reduced CPP (CPP < 60 mm Hg) were similar in Groups I and II (Table 2 ).
Brain Tissue O 2 Monitoring
The Group II patients received both an ICP and a PbtO 2 monitor (LICOX). Data were analyzed from a total of 6 Fig. 1 left) . The overall mean hospital LOS (including survivors and nonsurvi vors) was similar in the 2 groups (Group I: 19 ± 21.8 days; Group II: 23 ± 18.67 days; p = 0.29; Table 3 ). Of surviving Group I patients, 59% were discharged to a rehabilitation center, 13% to home, 21% to a skilled nursing facility, and 7% to another hospital. By contrast 6% of surviving Group II patients were discharged to a skilled nursing fa cility and the remaining patients were discharged home (8%) or to a rehabilitation center (86%; p < 0.01). Overall, 21 (39.6%) of the patients treated with ICP/CPP-guided management and 45 (64.3%) of those receiving PbtO 2 -guided management had a favorable outcome (GOS good or moderate disability) at 3 months (± 2 weeks) after TBI (p = 0.01, Fig. 1 right) .
Treatment of Compromised Brain O 2
The PbtO 2 based therapy was targeted and occurred in a physiologybased parallel process rather than as a lin ear therapy (therapy based on ICP alone). We identified 27 therapies that were used to treat compromised PbtO 2 in our institution during the study period (Table 4 ). The success of the individual treatments varied between 33 and 88%, although the efficacy of each separate thera peutic intervention cannot be reliably assessed because multiple interventions often were used simultaneously or in sequence. The therapy most commonly used, often transiently and with other therapies, to treat compromised PbtO 2 
Mortality Rate Associated with PbtO 2 -Guided Management
In the Group II patients, the mean daily PbtO 2 was significantly less in the 18 patients who died within 3 months of TBI (31.55 ± 20.64 mm Hg) than in those who survived (37. 
Discussion
In this study involving 123 patients with severe TBI we examined how a PbtO 2 based management strategy influenced patient mortality and short-term outcome at a Level I trauma center. We compared 70 patients who re ceived PbtO 2 directed care and ICP/CPP-based therapy to 53 historical controls who received only ICP/CPPbased therapy. Our results extend our preliminary ob servations 50 and suggest that PbtO 2 based therapy may be associated with reduced patient mortality and better shortterm outcome. In addition, among those patients who received PbtO 2 based therapy, survival was associat ed with successful treatment of episodes of compromised PbtO 2 . These results should be regarded as hypothesis generating and suggest that randomized trials are needed to examine whether PbtO 2 -directed care benefits patients with TBI.
Methodological Limitations
Our study has several potential limitations. First, the data were examined retrospectively and this may bias our results. Second, the study included only patients treated at a single institution, so it may lack external validity. Third, the sample size, 123 patients, although larger than our earlier study of 53 patients, 50 is still relatively small; however, the magnitude of the effect is reasonably large and the effect is both biologically plausible and consistent with TBI pathophysiology. Fourth, we do not have any information on adherence to the treatment protocols, and so it is conceivable that the results simply represent out come differences over time that have been observed on a national basis-rather than a specific therapy. However, the same team of physicians and nurses in the same ICU provided care to both patient groups using the same basic management strategy according to formal treatment para digms. Therapy to correct compromised PbtO 2 appears to be the only management parameter that was different be tween the 2 groups. Fifth, outcome was assessed approxi mately 3 months after TBI and within a range of 2 weeks before and after this date. Patient improvement can con tinue to occur after 3 months, and so it is conceivable that we may have underestimated outcome in some patients. This likely will affect both groups equally and is unlikely to have a significant effect on mortality rates. Neverthe less, it is conceivable that the difference in the treatment effect may be less than indicated by our data. Sixth, the mortality rate among the patients who received ICP/CPPbased therapy is higher than expected from outcome data published in some clinical trials of severe TBI. Selected patients usually are treated in clinical trials and this may bias the results. Our patients also did not have isolated head injuries since all had an ISS greater than 16. In ad dition, there is no established expected outcome for TBI and there is heterogeneity of TBI and patient demograph ics at each institution where the patients are treated. 10 It also is possible that outcome in the ICP/CPP group might have been better if induced hypothermia, hypertonic sa line, or decompressive hemicraniectomy had been used more frequently. However, the exact role of these thera pies in severe TBI is still being elucidated.
Finally, the study population was compared with his torical controls. There are wellknown limitations to this kind of analysis. From a statistical point of view, since pa tients in each group were treated according to a standard protocol and were similar with respect to age, sex, and admission GCS and ISS, as well as having comparable pathology on admission CT and meeting clearly delineat ed inclusion criteria, the study has some characteristics of a 2sample design but with 2 important exceptions: it was not randomized and the groups were not contempo raneous. More patients in the PbtO 2 group underwent a decompressive craniectomy. Since we are comparing 2 management strategies based on different physiological information rather than a single therapy (for example, a drug), it is perhaps not surprising that there is this man agement difference. What we do not know is whether this particular difference is associated with the use of a PbtO 2 monitor or represents another trend. In contrast to a difference in management and more importantly, the groups are matched when age, GCS, ISS, pathology on admission CT, and other variables are compared (Tables  1 and 2 ). These variables are among the most powerful independent prognostic variables after TBI 35 -that is, the outcome effect is likely to be associated with what we are examining, a management strategy or process of care, rather than patient characteristics. In our opinion, the results therefore suggest but do not prove that PbtO 2 directed TBI care may have a beneficial effect. Ideally, a randomized clinical trial will be needed to demonstrate the benefit of PbtO 2 directed TBI care. The data from this study provide some information needed to plan for such a trial.
1,37
Current Conventional TBI Management
Clinical and laboratory research demonstrate that not all neuron damage occurs at the time of injury, but dam age also occurs through secondary neuronal injury that evolves during the hours and days after TBI. 16, 28 Current TBI therapy is therefore centered on management of sec ondary brain injury, and, in particular, current TBI man agement emphasizes ICP reduction, in part to maintain CPP and prevent cerebral ischemia. This ischemia in creases the risk of poor TBI outcome. 7, 42 The association between increased ICP or reduced CPP and poor outcome is well described. 29, 34, 36 However, increased ICP is respon sible for fewer than half the episodes of cerebral isch emia, and cerebral infarction can occur despite normal ICP and CPP. 18, 24, 49, 58 Furthermore, recent PET studies in human patients after TBI suggest that mechanisms other than simple perfusionrelated ischemia may be associated with cellular hypoxia in the brain. 33 In addition, cerebral microdialysis studies in TBI suggest that an elevated lac tate/pyruvate ratio (that is, anaerobic metabolism) is inde pendent of CPP. 59 We also have observed that a third of patients with severe TBI who are adequately resuscitated according to published Advanced Trauma Life Support 2 and TBI guidelines 7, 42 -that is, CPP > 60 mm Hg-still have evidence of severe brain hypoxia (PbtO 2 ≤ 10 mm * The PbtO 2 -directed therapy was targeted and occurred in a physiology-based parallel process with ICP management. Therapies were titrated to effect and were often used in various combinations rather than singly. Abbreviations: EtCO 2 = end tidal CO 2 ; IV = intravenous; PEEP = positive end-expiratory pressure.
Hg) in the early hours after TBI. 51 These results may ex plain, in part, why therapies to improve CPP have not improved patient outcomes. 12, 43 Other therapies, including hypothermia, neuroprotection, steroids, and barbiturates, while effective in the laboratory, have not been success ful in patients. 6, 11, 14, 26, 37, 41, 42, 52 Together these data suggest that while an ICP monitor and ICP/CPP management are important in TBI, measures of other parameters or other management strategies also may be necessary.
Biological Plausibility of PbtO 2 -Directed TBI Care
The adult brain weighs about 2% of body weight yet consumes about 20% of the O 2 consumed by the entire body. More than 90% of this oxygen is used by the mi tochondria during aerobic metabolism. The pathophysi ological processes after TBI are complex; however, fol lowing severe TBI, a huge metabolic load is placed on brain tissue during a time when there is impaired O 2 delivery, compromised aerobic metabolism, and reduced cerebral blood flow. 5, 16, 21, 22, 30, 56 This results in cellular hy poxia. Consistent with the pathophysiological processes, histopathological examination of brain tissue, in some studies, demonstrates that 80-90% of patients who die of TBI have evidence of ischemic or hypoxic brain injury. Together these data suggest it is reasonable to assume that use of a PbtO 2 monitor and efforts to increase brain O 2 delivery may improve TBI outcome.
Several lines of converging experimental and clinical evidence suggest that PbtO 2 directed care is a potential TBI therapy. First, brain hypoxia (PbtO 2 < 15 mm Hg) is a welldescribed marker of poor outcome in many clini cal TBI studies. 13, [54] [55] [56] [57] [58] Second, reduced PbtO 2 is associ ated with independent neurochemical markers of brain ischemia; 20 by contrast, an increase in PbtO 2 is associated with improved brain metabolism in clinical TBI studies. 53 Third, strategies to augment PbtO 2 are associated with reduced secondary brain damage in experimental TBI models 40 and reduced infarct volumes in animal stroke models. 17, 47 Finally, Singhal et al. 46 recently demonstrated in a small, randomized clinical trial that high-flow O 2 therapy (to improve PbtO 2 ) was associated with a tran sient improvement in clinical deficits and MR imaging abnormalities in patients with acute cerebral ischemia. These various data are consistent with the 2 important observations in this paper: 1) PbtO 2 directed care is asso ciated with better outcome; and 2) successful correction of compromised PbtO 2 is associated with better survival after severe TBI.
Clinical Outcome and PbtO 2 -Directed TBI Care
There is limited research into how different tech niques to monitor patients' conditions, including use of ICP and PbtO 2 monitors, affect outcome after severe TBI. For example, while ICP monitors and ICP man agement have been used since the 1960s and represent a TBI "standard," their benefit to patient outcome has not been directly assessed in a clinical trial. 7 Therapy to optimize CPP, which is estimated from an ICP monitor, does not appear to benefit patients, 12, 43 and consequently there is debate about what constitutes optimal CPP after TBI. 15, 25, 38 Also, CPP guidelines have changed over the years; current guidelines suggest that CPP < 50 mm Hg or aggressive attempts to keep CPP > 70 mm Hg should be avoided. 8 During the time period in which our study was performed we used a CPP of 60 mm Hg to guide therapy. It is our contention that PbtO 2 guided management may help prevent cellular hypoxia and also may help establish what ICP or CPP is appropriate in an individual patient. This is important because there is marked heterogeneity in TBI pathology and pathophysiology, and therapies to treat ICP and CPP all are associated with potential del eterious effects.
The value of direct PbtO 2 monitoring and care based on this technique has undergone little direct study with respect to patient outcome. In a small series of 53 patients with TBI we observed that PbtO 2 based care was associ ated with a lower mortality rate than conventional ICP/ CPP therapy. 50 The sample size was small, and thus, the conclusions were preliminary. In the current series, which includes 123 new patients, we observed that PbtO 2 based care is associated with better outcome. Furthermore, sur vival is more likely when compromised PbtO 2 can be treated successfully. Exactly what constitutes the most effective method to correct compromised PbtO 2 remains unclear because we used many different strategies in a "causedirected manner," often in combination or in se quence. Certainly, our outcome measures (mortality, dis charge disposition, and shortterm GOS score) are crude. Nevertheless, they represent reasonable markers of out come. Future studies will need to examine neuropsycho logical and longterm functional outcome in survivors.
There is one other published study that examined PbtO 2 based therapy in TBI (although others have been published since this manuscript was submitted). 32 In this study using historical controls, Meixensberger et al. 32 stud ied 93 patients. There was a tendency, but no statistical difference, for patients who received PbtO 2 based rather than ICP/CPP-based treatment to have a better outcome. There are several important differences in the manage ment used by Meixensberger et al. and us. First, these au thors attempted to maintain CPP > 70 mm Hg. Clinical evidence now suggests that adherence to this CPP may be deleterious in some patients. 12, 15, 38, 42 In addition, a direct relationship between CPP and PbtO 2 is not observed in every patient, in large part because autoregulation fre quently is disturbed. 19, 44 Instead, we aimed to maintain CPP > 60 mm Hg, and in some patients tolerated a CPP between 50 and 60 mm Hg provided their PbtO 2 was nor mal (25-40 mm Hg). Second, Meixensberger et al. treated decreased PbtO 2 only by increasing CPP. By contrast, we used a "cause-specific" management protocol. 60 We have identified 27 different therapies used to correct compro mised PbtO 2 in our ICU and found that each, if used in a causedirected fashion, is successful in up to 80% of pa tients. These differences related to CPP may be important since therapies to increase CPP can adversely affect lung function, 12, 43 which in turn can compromise cellular oxy genation in the brain. 19 Finally, patients treated by Meix ensberger et al. received PbtO 2 therapy when their PbtO 2 was ≤ 10 mm Hg. At that threshold the brain is already severely hypoxic. By contrast, we initiated therapy when PbtO 2 was < 20 mm Hg. There are several reasons why we chose this threshold. Neuronal mitochondria, where the vast majority of brain oxygen is used, require a low intracellular PO 2 that corresponds to a minimum PbtO 2 threshold of about 20 mm Hg to maintain aerobic metab olism. 45 Brain hypoxia (PbtO 2 < 15 mm Hg) is associated with poor outcome; this association depends also on the duration of hypoxia. We have found that compromised PbtO 2 can take several minutes to respond to a therapy. We therefore start therapy to correct compromised PbtO 2 rather than wait for brain hypoxia to develop before start ing therapy. Consistent with this approach, van den Brink et al., 56 in a series of 101 patients with TBI, confirmed that neurological outcome depends not only on the depth but also the duration of brain hypoxia. This concept is con sistent with the wellknown threshold for cerebral blood flow beyond which neuronal injury progresses from re versible to irreversible.
While this study was not intended to answer how a PbtO 2 monitor altered care beyond data provided by an ICP monitor alone, we have learned several important concepts. First, there is a welldescribed association be tween secondary cerebral insults and poor outcome af ter TBI. Monitoring is essential to identify secondary cerebral insults, and it is believed that when recognized early, they can be better treated, thus improving patient outcome. There are many methods with which to moni tor brain physiology, but until 2007, an ICP monitor was the only recommended monitor. Certainly ICP monitors are useful, but several recent studies suggest that brain hypoxia or ischemia is common even when ICP is nor mal. 5, 24, 27, 33, 49, 51, 59 We believe a PbtO 2 monitor provides additional information about the health of the brain. Second, each and every treatment for elevated ICP and reduced CPP has associated adverse effects. When us ing a PbtO 2 monitor there is a tendency for us to tolerate slightly higher ICPs and so avoid some ICP management side effects. In addition, the effects of a particular treat ment, good or bad, can be recognized even if there is no alteration in ICP; and trends in PbtO 2 , rather than ICP thresholds alone, can be used to guide aggressive strate gies (for example, decompressive craniectomy). Third, in a few select patients, a PbtO 2 monitor has helped to iden tify extracerebral complications, particularly cardiopul monary complications, before other monitors do. Finally, there is marked heterogeneity in patients, including their premorbid condition and extracerebral physiology as well as the structural brain injury after TBI. The additional information provided by a PbtO 2 monitor allows care to be better targeted and individualized and so allows us to begin to move away from the "one size fits all" approach to severe TBI that still is prevalent. This is analogous to obtaining a culture and sensitivity analysis in a patient with a fever rather than simply giving antibiotics on an empirical basis.
Conclusions
Several studies suggest that a direct PbtO 2 monitor may be an ideal complement to ICP monitors in TBI man agement. 9, 19, 31, 39, 50, 51, [54] [55] [56] [57] [58] Our results, derived from retro spective analysis of data that was collected prospectively, suggest that therapy targeted at maintaining adequate O 2 tension is associated with better outcome after severe TBI than conventional ICP/CPP-based therapy. This manage ment strategy represents a paradigm shift in TBI care that will need to be confirmed in prospective studies.
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